Loading...
INDV logo

Indivior Pharmaceuticals, Inc.NasdaqGS:INDV Stock Report

Market Cap US$4.7b
Share Price
US$38.30
US$50
23.4% undervalued intrinsic discount
1Y173.4%
7D-0.5%
1D
Portfolio Value
​
View

Indivior Pharmaceuticals, Inc.

NasdaqGS:INDV Stock Report

Market Cap: US$4.7b

Indivior Pharmaceuticals (INDV) Stock Overview

Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. More details

INDV fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance1/6
Financial Health1/6
Dividends0/6

Rewards

Trading at 69.9% below our estimate of its fair value

Earnings are forecast to grow 13.84% per year

Became profitable this year

Analysts in good agreement that stock price will rise by 32.4%

Risk Analysis

Debt is not well covered by operating cash flow

Negative shareholders equity

Large one-off items impacting financial results


INDV Community Fair Values

Create Narrative

See what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Indivior Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Indivior Pharmaceuticals
Historical stock prices
Current Share PriceUS$38.30
52 Week HighUS$41.00
52 Week LowUS$13.45
Beta1.17
1 Month Change2.24%
3 Month Change30.72%
1 Year Change173.38%
3 Year Change67.98%
5 Year Change282.04%
Change since IPO259.62%

Recent News & Updates

Analysis Article • Jun 18

Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds

Indivior Pharmaceuticals (INDV) is back in focus after fresh attention on its role in treating opioid dependence, prompting investors to reassess the stock’s recent performance and current valuation based on publicly available financial metrics. See our latest analysis for Indivior Pharmaceuticals. The recent focus on Indivior Pharmaceuticals comes against a backdrop of steady gains, with a 30.72% 90 day share price return and a very strong 1 year total shareholder return of 175.54%,...
Seeking Alpha • Jun 09

Indivior: A Stronger Business Than When I First Covered It

Summary Indivior Pharmaceuticals (INDV) is focused on opioid addiction recovery, with SUBLOCADE as its flagship product. Sustained revenue from SUBLOCADE's monthly injection model differentiates INDV from generic addiction treatments. My previous Buy rating was based on the market undervaluing SUBLOCADE's earnings power and operational turnaround potential. The investment thesis has exceeded expectations, validating the strength of INDV's business model and product economics. Read the full article on Seeking Alpha

Recent updates

Analysis Article • Jun 18

Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds

Indivior Pharmaceuticals (INDV) is back in focus after fresh attention on its role in treating opioid dependence, prompting investors to reassess the stock’s recent performance and current valuation based on publicly available financial metrics. See our latest analysis for Indivior Pharmaceuticals. The recent focus on Indivior Pharmaceuticals comes against a backdrop of steady gains, with a 30.72% 90 day share price return and a very strong 1 year total shareholder return of 175.54%,...
Seeking Alpha • Jun 09

Indivior: A Stronger Business Than When I First Covered It

Summary Indivior Pharmaceuticals (INDV) is focused on opioid addiction recovery, with SUBLOCADE as its flagship product. Sustained revenue from SUBLOCADE's monthly injection model differentiates INDV from generic addiction treatments. My previous Buy rating was based on the market undervaluing SUBLOCADE's earnings power and operational turnaround potential. The investment thesis has exceeded expectations, validating the strength of INDV's business model and product economics. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Indivior: Trying To Break Addiction

Summary Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery. An analysis around INDV stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 13

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Summary Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x. With new competition from Brixadi, Sublocade maintains 80% market share across new patients. With LAI's low-7% penetration in BMAT, having both options on the market raises awareness for both drugs. The BMAT (Buprenorphine-Medically-Assisted-Treatment) market is expected to grow at a 9.9% CAGR over the next 8 years in the US. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback

Summary Indivior shares sold off on July 9th due to unexpected negative news from management, including the discontinuation of the schizophrenia drug Perseris and lower Sublocade guidance. Below, I argue why the market overreacted to Sublocade's lower FY24 guidance and why I expect Sublocade to continue growing. Current valuation indicates a FY24 EV/EBITDA multiple of sub 5x, offering an attractive entry point if Sublocade sales prove to be robust in the long term. Confidence in Sublocade was signalled by the board's approval of an "accelerated" $100 million repurchase program, which represents 6% of outstanding shares at the current share price of $12.5. Read the full article on Seeking Alpha

Shareholder Returns

INDVUS PharmaceuticalsUS Market
7D-0.5%-3.8%1.4%
1Y173.4%37.7%25.7%

Return vs Industry: INDV exceeded the US Pharmaceuticals industry which returned 36% over the past year.

Return vs Market: INDV exceeded the US Market which returned 25.1% over the past year.

Price Volatility

Is INDV's price volatile compared to industry and market?
INDV volatility
INDV Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: INDV has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: INDV's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014833Joe Ciaffoniwww.indivior.com

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.

Indivior Pharmaceuticals, Inc. Fundamentals Summary

How do Indivior Pharmaceuticals's earnings and revenue compare to its market cap?
INDV fundamental statistics
Market capUS$4.67b
Earnings (TTM)US$252.00m
Revenue (TTM)US$1.29b
18.5x
P/E Ratio
3.6x
P/S Ratio

Is INDV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INDV income statement (TTM)
RevenueUS$1.29b
Cost of RevenueUS$194.00m
Gross ProfitUS$1.10b
Other ExpensesUS$844.00m
EarningsUS$252.00m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)2.07
Gross Margin84.96%
Net Profit Margin19.53%
Debt/Equity Ratio-337.5%

How did INDV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/20 04:58
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Indivior Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Glen SantangeloBarclays
Graham Glyn ParryBofA Global Research
Chase KnickerbockerCraig-Hallum Capital Group LLC